DJIA 17,810.06 91.06 0.51%
NASDAQ 4,712.97 11.10 0.24%
S&P 500 2,063.50 10.75 0.52%
market minute promo


140.33 1.81 (1.31%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

PCYC $140.33 1.31%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $140.00
Previous Close $138.52
Daily Range $139.14 - $142.90
52-Week Range $82.51 - $154.89
Market Cap $10.6B
P/E Ratio 123.68
Dividend (Yield) $0.00 (0.0%)
Volume 917,239
Average Daily Volume 804,281
Current FY EPS $1.01






A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases. Website:

News & Commentary

Get Your Wallet Out: Global Drug Spending is About to Hit a Dubious Milestone

Global pharmaceutical spending is about to hit a dubious figure. Find out what this means for your pocketbook as well as your portfolio.

Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig

Pharmacyclics third-quarter results showed impressive sales growth for Imbruvica, a drug that competes against Gilead's Zydelig.

Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog

Pharmacyclics' (PCYC) CEO Robert Duggan on Q3 2014 Results - Earnings Call Transcript

Trade-Ideas: Pharmacyclics (PCYC) Is Today's Post-Market Leader Stock

Earnings Reaction History: Pharmacyclics Inc., 62.5% Follow-Through Indicator, 4.8% Sensitive

AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate Imbruvica In Hematolog

AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate Imbruvica In Hematologic Cancers

The Time Is Now For Northwest Biotherapeutics

Wainwright Sees TG Therapeutics As Take-Out Target

Pharmacyclics Up on Label Expansion Efforts for Imbruvica - Analyst Blog

See More PCYC News...

PCYC's Top Competitors

PCYC $140.33 (1.31%)
Current stock: PCYC
AMGN $162.81 (0.08%)
Current stock: AMGN
GILD $100.58 (-0.01%)
Current stock: GILD
BIIB $303.55 (1.49%)
Current stock: BIIB